BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moćko P, Kawalec P, Pilc A. Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. Clin Drug Investig 2017;37:25-37. [DOI: 10.1007/s40261-016-0459-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Larussa T, Basile A, Palleria C, Iannelli C, Vero A, Giubilei L, De Sarro C, Suraci E, Marasco R, Imeneo M, Russo E, Abenavoli L, De Sarro G, Luzza F. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Med Pharm Rep 2021;94:289-97. [PMID: 34430850 DOI: 10.15386/mpr-1897] [Reference Citation Analysis]
2 Stojek M, Jabłońska A, Adrych K. The Role of Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease. J Clin Med 2021;10:4055. [PMID: 34575166 DOI: 10.3390/jcm10184055] [Reference Citation Analysis]
3 Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brézin AP, Chee SP, Davis JL, Ramanan AV, Sonoda KH, Carreño E, Nascimento H, Salah S, Salek S, Siak J, Steeples L; Fundamentals of Care for Uveitis International Consensus Group. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology 2018;125:757-73. [PMID: 29310963 DOI: 10.1016/j.ophtha.2017.11.017] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 16.3] [Reference Citation Analysis]
4 Perera S, Yang S, Stott-Miller M, Brady J. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. J Health Econ Outcomes Res 2018;6:96-112. [PMID: 32685575 DOI: 10.36469/9791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Mcconachie SM, Wilhelm SM, Bhargava A, Kale-pradhan PB. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists. Ann Pharmacother 2018;52:571-9. [DOI: 10.1177/1060028018754896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:3-15. [PMID: 28449273 DOI: 10.1111/apt.14075] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 15.2] [Reference Citation Analysis]
7 Wilke T, Groth A, Long GH, Tatro AR, Sun D. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany. Clin Ther 2020;42:130-143.e3. [PMID: 31883702 DOI: 10.1016/j.clinthera.2019.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
8 Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Inflammatory Bowel Diseases 2018;24:286-95. [DOI: 10.1093/ibd/izx045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]